Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13430MR)

This product GTTS-WQ13430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13430MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15553MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ11213MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ6305MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ9840MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ10574MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ12821MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ13128MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ8947MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW